Review Article

Magnetic resonance imaging for prostate cancer: Comparative studies including radical prostatectomy specimens and template transperineal biopsy

Liam Toner 1, Mahesha Weerakoon 1, Damien M. Bolton 1,2, Andrew Ryan 3, Nikolas Katelaris 1, Nathan Lawrentschuk 1,2,4,

1 University of Melbourne, Department of Surgery, Urology Unit, Austin Health, Melbourne, Australia
2 Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia
3 Department of Pathology, TissuPath Specialist Pathology Services, Melbourne, Australia
4 Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

A R T I C L E   I N F O

Article history:
Received 13 March 2015
Accepted 31 March 2015
Available online 19 October 2015

Keywords:
Diagnosis
Histopathology
Magnetic resonance imaging
Prostatectomy
Prostatic neoplasms

A B S T R A C T

Purpose: Multiparametric magnetic resonance imaging (mpMRI) is an emerging technique aiming to improve upon the diagnostic sensitivity of prostate biopsy. Because of variance in interpretation and application of techniques, results may vary. There is likely a learning curve to establish consistent reporting of mpMRI. This study aims to review current literature supporting the diagnostic utility of mpMRI when compared with radical prostatectomy (RP) and template transperineal biopsy (TTPB) specimens.

Methods: MEDLINE and PubMed database searches were conducted identifying relevant literature related to comparison of mpMRI with RP or TTPB histology.

Results: Data suggest that compared with RP and TTPB specimens, the sensitivity of mpMRI for prostate cancer (PCa) detection is 80–90% and the specificity for suspicious lesions is between 50% and 90%.

Conclusions: mpMRI has an increasing role for PCa diagnosis, staging, and directing management toward improving patient outcomes. Its sensitivity and specificity when compared with RP and TTPB specimens are less than what some expect, possibly reflecting a learning curve for the technique of mpMRI.

Copyright © 2015 Asian Pacific Prostate Society, Published by Elsevier. All rights reserved.

1. Introduction

Prostate cancer (PCa) is the second most common cause of cancer death in Australian men and is the most commonly diagnosed internal malignancy with one in seven Australian men being diagnosed with PCa by the age of 75.1 PCa may first present with elevated prostate-specific antigen (PSA) on screening or symptomatically with lower urinary tract symptoms, bony pain from metastases or uncommonly with hematuria, urinary retention, or renal failure.2 The definitive diagnosis of PCa is generally made by a biopsy, typically transrectal ultrasound (TRUS)-guided biopsy. Staging is typically by a nuclear medicine bone scan or computed tomography–positron emission tomography.3

An influential work by McNeal et al in 19884 demonstrated trends in the zonal origin of PCa, particularly the predominance of malignancy within the peripheral zone (PZ) and hence its amenability to detection on digital rectal examination (DRE) and TRUS-guided biopsy. However, a minority of cancers arose from more anterior regions of the prostate leading to a newly articulated phenomenon “prostatic evasive anterior tumor syndrome (PEATS).” PEATS describes a subset of PCa which, due to anatomical location, may be missed by traditional investigations such as DRE and TRUS biopsy, both of which primarily focus on the PZ, but may be detected by multiparametric magnetic resonance imaging (mpMRI) or transperineal biopsy (TPB).5

Management of PCa depends on risk stratification, most commonly the Gleason score, TNM staging, and PSA level. Lower risk cancers may be indolent and require active surveillance (AS) involving (with local variation) monitoring PSA levels (serial PSA tests), DREs, biopsy, and possibly mpMRI or watchful waiting for
patients deemed not suitable for active treatment with curative intent by their treating clinician. Higher risk cancers may be treated with radical prostatectomy (RP), external beam or interstitial (brachytherapy) radiotherapy, androgen deprivation therapy, or a combination of these. Newer focal therapies are under investigation.3

This literature review aims to describe mpMRI and to explore the evolving role for PCa diagnosis and staging.3 The sensitivity and specificity of mpMRI reported in the literature is approximately 80–90% and 50–90%, respectively, when compared with RP and template TPB (TPPB) specimens.

2. Materials and methods

MEDLINE and PubMed database searches were conducted from August 2014 to January 2015 using combinations of the MeSH terms “prostate,” “prostatic neoplasia,” “diagnosis,” “magnetic resonance imaging,” and using specific search terms such as “mpMRI,” “multiparametric,” or “erMRI.”

3. Discussion

Multiparametric MRI (mpMRI) is an emerging technique that aims to improve upon the diagnostic sensitivity of prostate biopsy, and ultimately reduce the number of biopsies performed and better direct management decisions. The recently released 2014 National Institute for Health and Care Excellence (NICE) guidelines for management of PCa in the United Kingdom recommended an increasing role for mpMRI based on clinical and cost effectiveness. However, these guidelines recommended against utilizing mpMRI before biopsy due to insufficient cost benefit.1 It is important to distinguish multiphasic MRI from conventional 1.5-T MRI techniques without dynamic contrast-enhanced MRI (DCE-MRI) or diffusion-weighted imaging (DWI), which have been shown not to provide sufficiently reliable information for clinical decision making.7 The sequences involved in mpMRI are detailed in Table 1. Tables 2 and 3 summarize the literature regarding the diagnostic utility of mpMRI for PCa.

### 3.1. MRI after a negative TRUS

The NICE guidelines recommended consideration of an MRI after negative TRUS biopsy to assess the requirement for an additional biopsy.1 This particularly relates to PEATS, because anterior or apical tumors may be missed by TRUS biopsy but still be visible on mpMRI.5,8

### 3.2. Active surveillance

mpMRI has an emerging role within AS for low-grade disease, partly to minimize morbidity due to repeat biopsy.9,10 The Prostate Cancer Research International: Active Surveillance (PRIAS)—guideline and study for the expectant management of localized prostate cancer with curative intent study is a multicenter, international, ongoing study that includes a subgroup of men undergoing mpMRI as part of their AS for low-risk PCa. The PRIAS protocol includes an MRI 3 months after diagnosis, similar to the NICE guidelines recommending mpMRI for all men commencing AS.4 In addition, PRIAS includes yearly mpMRI and some targeted biopsies. The number, size, and prostate imaging-reporting and data system (PI-RADS) progression of visible lesions direct whether targeted biopsy is undertaken and longitudinal information will be collected regarding correlation of MRI with biopsy and RP specimens. PRIAS is expected to conclude in 2021 and may dictate the future role of mpMRI in AS.11,12

### 3.3. Preoperative staging

The NICE guidelines recommended mpMRI to investigate for regional nodal disease and the extent of the primary tumor in men with histologically proven PCa if the tumor growth affects management, such as in preoperative staging.1 Organ-confined disease enables an operative approach to spare the neurovascular bundle, minimizing concerns regarding positive surgical margins, and thereby reducing postoperative morbidity relating to erectile dysfunction without increasing mortality risk.12 mpMRI has been

| Magnetic resonance sequence | Technical details | Clinical implications |
|-----------------------------|-------------------|----------------------|
| DWI/ADC                     | The apparent diffusion coefficient (ADC) of a tissue dictates Brownian motion of water molecules within that tissue. Lower ADC within PCa may result from the replacement of fluid containing ducts with tightly packed glandular tissue. | ADC negatively correlates with tumor grade. DWI is more sensitive for tumors of a higher grade, stage and volume. |
| DCE                         | Malignant tissue has increased permeability and vascularity relative to normal tissue causing early enhancement and washout of the contrast agent. | Higher tumor grades correlate with proportionately earlier enhancement and washout. DCE-MRI may reduce accuracy within the TZ. |
| Magnetic resonance spectroscopy | Magnetic resonance spectroscopy detects increasing (choline + creatinine)/citrate ratios, which have been correlated with Gleason score. | A large clinical trial suggested that magnetic resonance spectroscopy provides little additional information compared with T2WI. Magnetic resonance spectroscopy may not be included in mpMRI sequences and is optional in the PI-RADS scoring system. |
| T1WI                        | Detects postbiopsy hemorrhage, which confounds other sequences. | |
| T2WI                        | Delineates the zonal anatomy of the prostate and capsule, and helps elucidate extracapsular extension. Suspicious characteristics include homogenous areas of low signal with ill-defined margins. | |

Note. From “The role of magnetic resonance imaging in the diagnosis and management of prostate cancer,” by J. Thompson, N. Lawrentschuk, M. Frydenberg, L. Thompson, and P. Stricker, USAZ, 2013, BJU Int, 112, p. 6–20; Also from “MRI for men undergoing active surveillance or with rising PSA and negative biopsies,” O. Raz, M. Haider, J. Trachtenberg, D. Leibovici, and N. Lawrentschuk, 2010, Nat Rev Urol, 7, p. 543–51.

ADC, apparent diffusion coefficient; DCE, dynamic contrast enhanced; DWI, diffusion-weighted imaging; mpMRI, multiparametric magnetic resonance imaging; MRI, magnetic resonance imaging; PCa, prostate cancer; PI-RADS, Prostate imaging and reporting data system; T1WI, T1-weighted imaging; T2WI, T2-weighted imaging; TZ, transition zone.
Table 2

mpMRI with RP reference standard.

| Reference                  | Thompson et al (19) | Chamie et al (41) | Junker et al (23) | Hoeks et al (40 a) | Delongchamps et al (42) | Yoshizako et al (29 a) | Villers et al (43) |
|---------------------------|---------------------|-------------------|-------------------|-------------------|------------------------|-----------------------|-------------------|
| Year                      | 2014                | 2014              | 2014              | 2013              | 2011                   | 2008                  | 2006              |
| Retrospective /prospective| Prospective         | Retrospective     | Prospective       | Retrospective     | Retrospective          | Retrospective         | Prospective       |
| Age (y)                   | 62                  | 61, mean          | 63, mean          | 67                | 63                     | 65                    | 63                |
| Prostate-specific antigen | 5.6                 | 5.6, mean         | 7.3, mean         | 9                 | 7                      | NR                    | 9.9               |
| Sensitivity (%)           | 98                  | 96                | 97                | 65                | 78                     | NR                    | 77                |
| Specificity (%)           | 43                  | 46                | 79                | 97                | NR                     | NR                    | 91                |
| Negative predictive value (%)| 75            | 92                | NR                | NR                | NR                     | NR                    | NR                |
| Positive predictive value (%)| 91             | 66                | NR                | NR                | NR                     | NR                    | NR                |
| N                         | 48                  | 115               | 50                | 63 (a)            | 57                     | 35 (a)                | 24                |
| MRI sequence              | T2, DWI, DCE        | T2, DWI           | T2, DWI, DCE      | T2, DWI, DCE      | T2, DWI, DCE           | T2, DWI, DCE          | T2, DWI           |
| Field strength (T)        | 1.5/3 alternating   | 3                 | 3                 | 3                 | 1.5                    | 1.5                   | 1.5               |
| Coil                      | PPA                 | ERC               | PPA               | ERC               | PPA                    | PPA                   | PPA               |
| No. of readers, experience| 2, 1,000 prostate MRI reported | 1, Experienced | 1, Experienced | 4, 3–10 y | 2, Experienced | 2 y, 13 y, and 15 y | 2 y, 15 y, and 4 y |
| Radiologist blinding      | NR                  | Blinded to clinical | Blinded to clinical | PCA known, not location | Blinded to clinical | PCA known, not location | Blinded to biopsy and histopathology |
| Time from MRI to RP       | NR                  | NR                | 1 d               | NR                | NR                     | 1–7 wk, median 4     | 30 d, mean       |
| Reporting system          | PI-RADS             | Epstein criteria or | PI-RADS          | Likert            | Likert                 | Likert                | Likert            |
| Significant cancer definition | GS ≥ 7, GS – 6 CL ≥ 5 mm or 20% cores positive | pT3, GS ≥ 4 + 3 | Any PCa          | Any PCa           | Any PCa                | Any PCa              | Any PCa           |

Age and PSA are median values unless labeled as mean. PI-RADS 3–5 was considered positive.

(a) Only considers TZ PCa.

(b) Paper reports other definitions.

ADC, apparent diffusion coefficient; CL, core length; DCE, dynamic contrast enhanced; DWI, diffusion-weighted imaging; ERC, endorectal coil; GS, Gleason score; mpMRI, multiparametric magnetic resonance imaging; MRI, magnetic resonance imaging; NR, not recorded; PCA, prostate cancer; PI-RADS, prostate imaging-reporting and data system; RP, radical prostatectomy; TZ, transition zone; UCL, University College London.
Table 3
mpMRI with TPB reference standard.

| Reference                  | Year | Retrospective/prospective | Age (y) | Prostate-specific antigen | Sensitivity (%) | Specificity (%) | Negative predictive value (%) | Positive predictive value (%) | N with prostate cancer | MRI sequence | Field strength (T) | No of readers, experience | Radiologist blinding | Time from MRI to TPB | Number of cores | Prior negative biopsy | Significant cancer definition | Reporting system | Prior positive biopsy | Reporting system | Significant cancer definition |
|---------------------------|------|---------------------------|---------|---------------------------|----------------|----------------|-------------------------------|-------------------------------|------------------------|--------------|-------------------|-----------------------------|-------------------|-------------------|----------------|---------------------|-----------------------------|----------------|---------------------|-------------------|---------------------|
| Pepe et al 42             | 2014 | Prospective               | 65      | 10.4                      | 83             | 72             | 88                            | 79                            | 168                    | T2, DWI, DCE, MRS | 3                | 2, NR             | Blinded to clinical       | 3–10 d           | 6–35, median 28     | median 30, two targeted | Yes                | G5 ≥ 7, G5 = 6 CL ≥ 5 mm or 20% cores positive | PPA                        | NR                  | Mainly            | UCL 1, UCL 2 (a) and PIRADS 4 |
| Thompson et al 19         | 2014 | Prospective               | 62      | 5.6                       | 93             | 53             | 52                            | 98                            | 150                    | T2, DWI, DCE    | 1.5/3 alternating | PPA                        | Blinded to clinical       | 1, 4 y | 24–40, two to four targeted | median 30, two targeted | Yes                | G5 ≥ 7, G5 = 6 CL ≥ 6 mm | PPA                        | NR                  | Mainly            | UCL 1, UCL 2 (a) and PIRADS 4 |
| Grey et al 35             | 2014 | Prospective               | 65, mean| 11.7, mean                | 97             | 60             | 98                            | 49, 58, 84 (b)                | 77                     | T2w, DWI      | 1.5/3 alternating | PPA                        | Blinded to clinical       | 1, 4 y | 24–40, two to four targeted | median 30, two targeted | Yes                | G5 ≥ 7, G5 = 6 CL ≥ 6 mm | PPA                        | NR                  | Mainly            | UCL 1, UCL 2 (a) and PIRADS 4 |
| Abd-Alazzee et al 25      | 2014 | Retrospective             | 62      | 5.8                       | 98, 94         | 22.23          | 98                            | 21, 34                        | 201                    | T2, DWI, DCE  | T2w, DWI, DCE | Blinded to biopsy       | Blinded to biopsy          | 1, 4 y | 24–40, two to four targeted | median 30, two targeted | Yes                | G5 ≥ 7, G5 = 6 CL ≥ 6 mm | PPA                        | NR                  | Mainly            | UCL 1, UCL 2 (a) and PIRADS 4 |
| Abd-Alazzee et al 32      | 2014 | Prospective               | 62      | 5.8                       | 90, 76         | 42.42          | 98                            | 26, 38                        | 141                    | T2, DWI, DCE  | T2, DWI, DCE | Blinded to biopsy       | Blinded to biopsy          | 1, 4 y | 24–40, two to four targeted | median 30, two targeted | Yes                | G5 ≥ 7, G5 = 6 CL ≥ 6 mm | PPA                        | NR                  | Mainly            | UCL 1, UCL 2 (a) and PIRADS 4 |
| Arumainayagam et al 31    | 2013 | Retrospective             | 64, mean| 10                        | 91–94, 84–89   | 64–81, 58–73   | 95, 79                        | 35–45, 49–63 (c)              | 54                     | T2, DWI, DCE  | T2, DWI, DCE | Blinded to biopsy       | Blinded to biopsy          | 1, 4 y | 24–40, two to four targeted | median 30, two targeted | Yes                | G5 ≥ 7, G5 = 6 CL ≥ 6 mm | PPA                        | NR                  | Mainly            | UCL 1, UCL 2 (a) and PIRADS 4 |

(a) Range is from different radiologists
(b) PPV for PIRADS 3, 4, and 5, respectively.
(c) UCL 1: Gleason score of over 4 + 3 and/or maximum cancer core length (CCLmax) of 6 mm or more; UCL 2: Gleason score of 3+4 or more and/or CCLmax of 4 mm or more.33,36,37
(d) Paper reports other definitions.

DCE, dynamic contrast enhanced; DWI, diffusion-weighted imaging; G5, Gleason score; mpMRI, multiparametric magnetic resonance imaging; MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NR, not recorded; PIRADS, prostate imaging-reporting and data system; PPA, pelvic-phased array; TPB, transperineal biopsy; UCL, University College London.

Age and PSA are median values unless labeled as mean. PIRADS 3–5 was considered positive.
shown to have a high positive predictive value (PPV) of around 90% in a high-risk cohort and a negative predictive value (NPV) of around 90% in a low-risk cohort for predicting extracapsular extension versus organ-confined disease. However, Billing et al reported a PPV and NPV of approximately 70% in the general case, which serves to remind that all MRI reports must be viewed in their clinical context.

3.4. mpMRI sequences

A 2014 European Consensus Panel and the European Society for Urogenital Radiology (ESUR) agreed that multiphasic MRI should involve various submodalities such as T1-weighted images (T1WIs), T2-weighted images (T2WIs), DWI and DCE as different sequences provide an additive benefit to accuracy. The role of MR spectroscopy is less clear. The 2014 NICE guidelines only recommend obtaining T2WI and DWI images and provide no recommendations regarding field strength or the use of an endorectal coil (ERC).

3.5. Magnetic field strength and ERCs

3-T MRI may be preferred due to increased spatial resolution and signal-to-noise ratio. However, this may not improve diagnostic accuracy. ERC, compared with a pelvic-phased array (PPA), may be used to locally increase spatial resolution while also causing significant patient discomfort. Improvements in diagnostic accuracy are less clear. A 2014 International Consensus Panel recommended the use of ERC at 1.5 T, but considered 3 T as optional, by contrast, the ESUR considers them entirely optional.

3.6. Scoring system for image interpretation

In 2012, the ESUR published a structured reporting system known as the PI-RADS and recommendations on standardizing the mpMRI protocol. The aim of these guidelines was to improve the diagnostic accuracy of mpMRI for PCa, to improve communication between radiologists, and to standardize the literature for better comparisons between studies. A PI-RADS score has components from different MRI sequences and an overall score from one to five, with higher numbers reflecting an increasing probability of PCa risk and aggression. Prior to these publications, many studies used more subjective Likert scales, which have subsequently shown to have greater interobserver variability.

Some authors describe the PI-RADS system as a work in progress due to ongoing controversy surrounding MRI protocols and the definition and treatment of clinically significant PCa. PI-RADS 3 is considered “equivocal” and it is unclear whether this should be considered positive or not; in particular, the morbidity due to overtreatment of PCa is a concern. The trend is that if equivocal results are included, sensitivity is higher while specificity is lower. Some authors report both and the difference in quantitative results is substantial. For example, Abd-Alaeezeez et al reported, for University College London (UCL) definition 2, sensitivities of 94% and 68% with specificities of 23% and 69% for PI-RADS of 3 or more and 4 or more, respectively.

Typically, it is local practice in Melbourne, Australia, for a radiologist to recommend a biopsy of a PI-RADS 3 lesion. Fig. 1 illustrates the correlation between a PI-RADS 5 lesion identified on mpMRI and an RP specimen.

3.7. Reference standard controversy

There is an ongoing controversy surrounding the reference standard to which mpMRI is compared. Various authors advocate comparing MRI with transrectal biopsy, TPB, or whole-mounted prostatectomy specimens. Transrectal biopsies miss 20–30% of clinically significant tumors, typically caused by undersampling of the apex, transition zone (TZ), and anterior horns of the PZ. Template-guided TPB provides a more comprehensive sample. RP whole-mount specimens minimize any sampling error, but exacerbate selection error because men with low-risk disease, who are unfit for surgery, who choose alternative treatments, or those without PCa are not sampled. By focusing on men with high-risk PCa, this approach limits the investigation of the NPV and the role for MRI to reduce unnecessary biopsies. Thompson et al used TTPB and RP and reported similar results.

3.8. Benign disease mimicking carcinoma

Benign disease such as benign prostatic hyperplasia, biopsy changes, fibrosis, prostatitis, and prostatic intraepithelial neoplasia can mimic the appearance of cancer on mpMRI. However, Junker et al demonstrated that such mimics are almost exclusively mistaken low-grade carcinoma as indicated by a PI-RADS score of 3 or less.

3.9. Timing of MRI postbiopsy

A 2014 European Consensus recommended that mpMRI should be conducted at least 8 weeks after the biopsy to minimize the confounding effect of postbiopsy hemorrhage. Hemorrhage can cause decreased T2 signal potentially masking or mimicking tumors and can involve areas quite distant from the needle trajectory. However, a 2012 study by Rosenkrantz et al involving 44 patients showed that lengthy delay might not be necessary, as hemorrhage can reliably be demonstrated on T1WI.

3.10. Definition of clinically significant PCa

As mentioned earlier, PCa can range from indolent to lethal. Appropriate risk stratification is critical to guiding management, to both reduce morbidity from overtreatment and mortality from undertreatment. There is considerable variation in the definition of “clinically significant” PCa. For example, in 2008, Yoshizako et al included cancers with Gleason score 3 + 3 and no size restrictions. In 2011, Haffner et al included cancers with Gleason score 3 + 3 and no size restrictions. In 2015, Junker et al defined low grade as 3 + 4 or less and high grade as 4 + 3 or more without mention of core length. In 2014, Abd-Alaeezeez et al reported results for five different definitions of clinical significance based around the Gleason score (either ≥4 + 3 or ≥3 + 4) and individual cancer core length (either ≥6 mm or ≥4 mm) or combinations of the two. More recently, papers from UCL have attempted to standardize reporting with the following definitions. UCL 1: Gleason score of over 4 + 3 and/or maximum cancer core length (CCLmax) of 6 mm or more; UCL 2: Gleason score of 3 + 4 or more and/or CCLmax of 4 mm or more. More exclusive definitions of clinically significant PCa tend toward higher sensitivities compared with more inclusive definitions, with small decreases in specificities. Arumainayagam et al and Abd-Alaeezeez et al, compared the more exclusive UCL 1 with the more inclusive UCL 2, and showed that sensitivity increases by 4–16% and specificity decreases by 0–3%. Thompson et al analyzed four definitions and reported smaller differences of 0–3% for both sensitivity and specificity.

3.11. Blinding

The studies in Tables 2 and 3 all used some form of blinding, but the details varied. One would expect that a stricter blinding...
protocol results in less diagnostic accuracy, but this is not evident in these tables so the effect is likely small.

3.12. Patient population and biopsy indication

By definition, sensitivity and specificity are independent of disease prevalence, whereas PPV and NPV are not. Despite this, the differing indications for mpMRI alter the diagnostic accuracy. For example, Grey et al\(^{34}\) reported sensitivity varying from 85% to 100% across primary biopsy, AS, and previous negative biopsy groups. The effects were more pronounced for NPV varying from 27% to 77%.\(^{33,34}\) The two 2014 studies by Abd-Alazeez et al\(^{25,32}\) primarily differ in the MRI indication as they are from the same institution over similar periods. In the primary biopsy setting, with significant PCa defined by UCL 2, sensitivity and specificity were reported as 94% and 23%, respectively, compared with 76% and 42% respectively in the repeat biopsy setting. This variation may be accounted for by the systematic differences between the groups in terms of tumor size and location such as PEATS being more common in the previous negative biopsy group.\(^{5}\)

3.13. Comment on specific papers

Tables 2 and 3 summarize the literature regarding the diagnostic utility of mpMRI for PCa. They demonstrate the wide range of results and heterogeneity in terms of patient population, test indication, study design, MRI protocol, scoring system, radiologist experience, biopsy protocol, significant cancer definition, and reference standard, all of which confound direct comparison. Several papers were excluded as they only investigated the MRI sequences individually and not their combined utility.\(^{25-37}\) A 2014 meta-analysis by de Rooij et al\(^{38}\) and a 2015 meta-analysis by Fütterer et al\(^{39}\) were excluded as the relevant studies were already included, and thus, the information was considered redundant. The results of the meta-analyses largely agree with Tables 2 and 3 with some differences as other reference standards such as TRUS biopsy or MRI-guided biopsy were included.

The difficulty in imaging the TZ was illustrated by Hoeks et al\(^{40}\) as they reported disappointing results, with no significant improvement in mpMRI (including both DCE and DWI—MRI) compared with T2WI MRI alone with accuracies of 66% and 68%, respectively. These numbers are comparable to those obtained by a smaller study Yoshizako et al\(^{29}\) where accuracy decreased from 83% to 79% after DCE was added to T2WI and DWI for TZ PCa. Delongchamps et al\(^{22}\) again showed the difficulty in imaging the TZ, reporting a maximum sensitivity and specificity of 71% and 98% for the TZ (results not statistically significant), which is less favorable than the PZ with 80% and 97%, respectively. This suggests that PCa location is another confounding factor for comparing studies.

Delongchamps et al\(^{22}\) found that the addition of DCE to an mpMRI protocol reduces accuracy within the TZ and reported sensitivity and specificity of 53% and 83%, respectively, if DCE was included; however, upon excluding DCE, they reported sensitivity and specificity of 71% and 98%, respectively.\(^{22}\) This was supported by Junker et al\(^{23}\) who reported a sensitivity and specificity within the TZ as 53% and 83%, respectively, if DCE was included compared with 71% and 98% if DCE was excluded.\(^{23}\) Junker et al\(^{23}\) subsequently recommended that the PI-RADS score developed in 2012 by the ESUR be amended to reflect this finding.

Chamie et al\(^{41}\) demonstrated that the additional benefit of DWI in mpMRI is most significant for higher grade disease, which is particularly relevant as overtreatment of clinically insignificant disease is a concern. Pepe et al\(^{42}\) also reported that the diameter of lesions identified on mpMRI correlated with aggressiveness. Grey
et al\textsuperscript{44} reported that out of 88 patients with a negative MRI, only two had low-volume Gleason score 3 + 4 PCs on TPB (98% NPV). In addition, Thompson et al\textsuperscript{45} suggested that avoiding biopsy of PI-RADS 1 or 2 MRI lesions may reduce unnecessary biopsies by 50% at the cost of delaying diagnosis of Gleason score 3 + 4 in 1% of patients. In both papers, no higher-grade disease was missed. This suggests that MRI may have a role in reducing unnecessary biopsies and associated morbidity.\textsuperscript{44}

The two oldest studies by Villers et al\textsuperscript{43} and Yoshizako et al\textsuperscript{29} illustrated the evolution of mpMRI protocol across time. Villers et al\textsuperscript{43} did not include DWI as their study preceded a number of guidelines advocating its use.\textsuperscript{18,42} Further, both authors used a 1.5-T field strength without an ERC, which results in a lower spatial resolution and is now perhaps thought to be insufficient.\textsuperscript{18}

Grey et al\textsuperscript{45} described a particular patient whose PCa was missed by mpMRI. The reference test (TPB) was performed 10 months after the MRI (compared with the mean of 43 days) so it is possible the cancer had either increased in volume or progressed in grade and the original PI-RADS score of 1 or 2 may have been accurate at the time.\textsuperscript{45} This case suggests that an additional confounding factor is the time from MRI to biopsy and then to RP.

3.14. Interobserver variability and a learning curve

Interobserver variability and learning curves are likely contributing factors to the diversity of results in different studies of mpMRI. The effects are greater when Likert scale scoring systems are employed, as they rely heavily on the experience of senior radiologists, and the effects are lessened for more well-defined scoring systems, such as PI-RADS. Gaziev et al\textsuperscript{44} demonstrated a significant learning curve for PCa detection with MRI reporting on a Likert scale. The 2-year prospective study reported an increase in cancer detection from 42% to 81%. Vache et al\textsuperscript{41} compared different scoring systems for the diagnosis of PCs on mpMRI. Significant interobserver variability occurred with the subjective Likert scoring system with area under the curve (AUC) scores varying from 0.88 to 0.81. Interobserver variation was minimal across the more rigid scoring systems as PI-RADS AUC varied from 0.75 to 0.76. Pokorny et al\textsuperscript{46} using PI-RADS, demonstrated no significant difference in accuracy between junior and senior radiologists and a urologist after the protocol had been implemented for 18 months. Accuracy did not increase with time across the 6-month study.

3.15. Future studies

The UCL Hospital is undertaking the Prostate Imaging Compared to Transperineal Ultrasound Guided Biopsy for Significant Prostate Cancer Risk Evaluation (PICTURE) study and the multicenter PRIAS Prostate MRI Imaging Study: Evaluation of Multi-parametric Magnetic Imaging in the Diagnosis and Characterisation of Prostate Cancer (PRIAS) designed to prospectively assess the NPV of mpMRI and the role to reduce biopsies.\textsuperscript{47} Both studies are expected to be completed in 2014/2015.\textsuperscript{47}

3.16. MR-guided biopsy

Lawrence et al\textsuperscript{38} electronically aligned and fused mpMRI images with three-dimensional real-time TRUS imaging for targeted biopsy. Pokorny et al\textsuperscript{45} described in-bore MR-guided prostate biopsy reporting sensitivity and specificity of 92% and 97%, respectively, for intermediate and high-grade PCs.\textsuperscript{45}

In conclusion, mpMRI has an increasing role for PCa diagnosis, staging, and directing management toward improving patient outcomes. The sensitivity and specificity of mpMRI reported in the literature is approximately 80–90% and 50–90% when compared with RP and TTPB specimens. This is less than what some expect, possibly reflecting a learning curve for the technique of mpMRI.

Conflicts of interest

None declared.

References

1. Australian Institute of Health and Welfare. Cancer in Australia: an overview 2014. Canberra: Australian Institute of Health and Welfare; 2014.
2. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, Campbell-Walsh urology. 10th ed. Philadelphia: Saunders; 2012.
3. Graham J, Kirkbride P, Cann K, Hasler E, Prettyjohns M. Prostate cancer: summary of updated NICE guidance. BMJ. 2014;348:f7524.
4. McNeal JE, Redwine EA, Freha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;12:897–906.
5. Lawrence A, Haider MA, Daljert N, Evans A, Toi A, Finelli A, et al. ‘Prostatic evasive anterior tumours’: the role of magnetic resonance imaging. BJU Int. 2010;105:1231–6.
6. Gupta RT, Kauffman C, Polascik TJ, Taneja S, Rosenkrantz A. The state of prostate MR guidelines 2012. Eur Radiol. 2012;22:746–50.
7. Johnston R, Wong LM, Warren A, Shah N, Neil D. The role of 1.5 Tesla magnetic resonance imaging in staging prostate cancer. ANZ J Surg. 2013;83:234–8.
8. Thompson J, Lawrentschuk N, Frydenberg M, Thompson L, Stricker P, USANZ. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int. 2013;112:6–20.
9. Lee DJ, Ahmed HU, Moore CM, Emberton M, Ehdiaie B. Multiparametric magnetic resonance imaging in the management and diagnosis of prostate cancer: current applications and strategies. Curr Urol Rep. 2015;16:51.
10. Gaziev G, Haider M, Trachtenberg J, Leibovich B, Lawrentschuk N. MRI for men undergoing active surveillance or with rising PSA and negative biopsies. Nat Rev Urol. 2010;7:543–51.
11. Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. Eur Urol. 2013;63:997–603.
12. Bostwick D, Alberts A. PRIAS Project 2015 [Internet]. [cited 2015 Oct 3]. Available from: https://www.prias-project.org/.
13. Somford DM, Hamoen EH, Fütterer JJ, van Basten JP, Hulsbergen-van de Kaa CA, van der Velden BC. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol. 2013;190:1728–34.
14. Gupta RT, Faridi KF, Singh AA, Passoni NM, Garcia-Reyes K, Madden JF, et al. Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. Urol Oncol. 2014;32:1292–9.
15. Tanaka K, Shimamura K, Muramaki M, Takahashi S, Miyake H, Fujisawa M. Efficacy of using three-tesla magnetic resonance imaging diagnosis of capsule invasion for decision-making about neurovascular bundle preservation in robotic-assisted radical prostatectomy. Korean J Urol. 2013;54:437–41.
16. Billing A, Buchner A, Stief C, Roosen A. Preoperative mp-MRI of the prostate provides little information about staging of prostate carcinoma in daily clinical practice. World J Urol. 2015;33:923–8.
17. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Velleirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol. 2012;22:746–57.
18. Muller BG, Fütterer JJ, Gupta RT, Katz A, Kirkham A, Kurhanewicz J, et al. The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU Int. 2014;113:218–27.
19. Thompson J, Moses D, Shinier R, Brenner P, Delprado W, Ponsky L, et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol. 2014;192:67–74.
20. Bratan F, Nief E, Melodelima C, Chesnais A, Souchon R, Mege Lechevallier F, et al. Influence of imaging and histological factors on prostate cancer detection and localisation on multiparametric MRI: a prospective study. Eur Radiol. 2013;23:2019–29.
21. Vache T, Bratan F, Mege Lechevallier F, Roche S, Rabiloud M, Rouviere O. Characterization of prostate lesions as benign or malignant at multiparametric MR imaging: comparison of three scoring systems in patients treated with radical prostatectomy. Radiol. 2014;272:446–55.
22. Delongchamps NB, Rouanne M, Flam T, Beuvon F, Liberator M, Zerbib M, et al. Multiparametric magnetic resonance imaging in the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging. BJU Int. 2011;107:1411–8.
23. Junker D, Quentin M, Nagele U, Edlinger M, Richenberg J, Schafer G, et al. Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis. World J Urol. 2015;33:1023–30.
24. Westphalen A, Rosenkrantz A. Prostate imaging reporting and data system (PI-RADS): reflections on early experience with a standardized interpretation scheme for multiparametric prostate MRI. AJR Am J Roentgenol. 2014;202:121–3.
25. Abd-Alaeeez M, Kirkham A, Ahmed HU, Arya M, Anastasiadis E, Charman SC, et al. Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard. Prostate Cancer Prostatic Dis. 2014;17:40–6.

26. Ahmed HU, Emberton M. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int. 2009;104:269–70.

27. Ong W, Weerakoon M, Huang S, Paul E, Lawrentschuk N, Frydenberg M, et al. Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasound-guided biopsy: the Victorian Transperineal Biopsy Collaboration experience. BJU Int. 2015;116:568–76.

28. Rosenkrantz AB, Miosi TC, Hindman N, Lim RP, Kong MX, Babb JS, et al. Impact of delay after biopsy and post-biopsy haemorrhage on prostate cancer tumour detection using multi-parametric MRI: a multi-reader study. Clin Radiol. 2012;67:e83–90.

29. Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N, et al. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol. 2008;49:1207–13.

30. Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, Jones JS, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011;108:E171–8.

31. Arumainayagam N, Ahmed H, Moore C, Freeman A, Allen C, Sohaib SA, et al. Multiparametric MRI for imaging of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. Radiology. 2013;268:761–9.

32. Abd-Alaeeez M, Ahmed HU, Arya M, Charman S, Anastasiadis E, Charman A, et al. The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level—can it rule out clinically significant prostate cancer? Urol Oncol. 2014;32:45.

33. Rosenkrantz AB, Miosi TC, Borofsky MS, Scionti SS, Grasso M, Taneja SS. 3.0 T multiparametric prostate MRI using pelvic phased-array coil: utility for tumor detection prior to biopsy. Urol Oncol. 2013;31:1430–5.

34. Grey AD, Chana M, Popert R, Wolfke K, Liyanage S, Acher PL. Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI-RADS) scoring in a transperineal prostate biopsy setting. BJU Int. 2015;115:728–35.

35. Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T, et al. Multi-parametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol. 2011;186:1818–24.

36. Turkbey B, Pinto PA, Mani H, Bernardo M, Pang Y, McKinney YL, et al. Prostate cancer: value of multiparametric MRI at 3 T for detection—histopathologic correlation. Radiology. 2010;255:89–99.

37. Kuru T, Roethke M, Rieker P, Roth W, Fenchel M, Hohenfellner M, et al. Histology-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate. BJU Int. 2013;112:1080–7.

38. de Rooij M, Hannoen EH, Fütterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol. 2014;202:343–51.

39. Fütterer J, Briganti A, de Visschere P, Emberton M, Giannarini G, Kirkham A, et al. Can clinically significant prostate cancer be detected with multi-parametric magnetic resonance imaging? A systematic review of the literature. Eur Urol. 2015;68:1045–53.

40. Hoeks CM, Hambrock T, Yakar D, Hulsbergen-van de Kaa CA, Feuth T, Witjes JA, et al. Transition zone prostate cancer: detection and localization with 3-T multiparametric MRI imaging. Radiology. 2013;266:207–17.

41. Chame K, Senn GA, Finley DS, Tan N, Margolis DJA, Raman SS, et al. The role of magnetic resonance imaging in delineating clinically significant prostate cancer. Urology. 2014;83:369–75.

42. Pepe P, Garufi A, Priolo G, Dibenedetto G, Salemi M, Pennisi M, et al. Accuracy of 3 Tesla pelvic phased-array multiparametric MRI in diagnosing prostate cancer at repeat biopsy. Arch Ital Urol Androl. 2014;86:336–9.

43. Villers A, Puech P, Mouton D, Leroy X, Ballereau C, Lemaître L. Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer: prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2014;66:22–9.

44. Simmons LA, Ahmed HU, Moore CM, Punwani S, Freeman A, Hu Y, et al. The PICTURE study—prostate imaging (multi-parametric MRI and Prostate Histoscanning™) compared to transperineal ultrasound guided biopsy for significant prostate cancer risk evaluation. Contemp Clin Trials. 2014;37:69–83.

45. Emberton M, PROstate MRI imaging study [Internet]. Medical Research Council: clinical trials unit; 2011 [cited 2015 Jan 3]. Available from: http://www. isrctn.com/ISRCTN16082556.

46. Lawrence E, Tang SY, Barrett T, Koo B, Goldman D, Warren AJ, et al. Prostate cancer: performance characteristics of combined T2W and DW-MRI scoring in the setting of template transperineal re-biopsy using MR-TRUS fusion. Eur Radiol. 2014;24:1497–505.
